The Impact of Trump on Biotech Investments: A Case for Steering Clear

The Impact of Trump on Biotech Investments: A Case for Steering Clear

Pharmaceutical Stocks in Chaos: Donald Trump Shakes Up the Industry

The pharmaceutical and biotech sector is experiencing turbulence once more. Tuesday saw shares of Amgen, Regeneron Pharmaceuticals, Merck, and Axsome Therapeutics plummet by up to seven percent at the stock exchange. The culprit? Uncertainty surrounding Donald Trump's policies, which time and time again have sent medical stocks tumbling.

Trump's Policy Predicament

The recent dip in pharmaceutical stocks can be attributed to custom duties announced by Trump Monday, which will also impact drug manufacturers. With the details yet to unfold, the mention of pharmaceutical products could have far-reaching consequences for the industry.

It's possible that the duties will affect not only the drugs themselves but also products used in the production of active ingredients or medical devices. Particularly at risk are biotech companies with no or minimal revenue streams.

Investing in a Stormy Sea?

In these uncertain times, companies like Amgen, Eli Lilly, and AbbVie, with stable earnings and diversified product pipelines, are well-prepared to weather the storm. Conversely, small biotech firms without commercial products, such as Viking Therapeutics, may face challenging times.

Also read: The Amazing Upside: Why Cathie Wood Keeps Buying this Stock in 2025

Or: The Return of the Mighty Seven? Morgan Stanley Predicts Recovery in US Stocks

Enrichment Insights

Donald Trump's policies hold numerous ramifications for the pharmaceutical and biotech sector, affecting companies like Amgen, Regeneron, Merck, and Axsome Therapeutics in various ways:

Regulatory Environment and Domestic Production

1. Streamlined Approvals: An executive order aimed at promoting domestic drug manufacturing could benefit these companies by reducing regulatory approvals' timeframe and easing the construction or expansion of manufacturing facilities in the U.S. [2][3].
2. Increased Inspections for Foreign Facilities: The order may also increase inspections and fees for foreign manufacturing plants, making it costlier and more challenging for these firms if they maintain significant overseas operations.

Tariffs and Trade Policies

1. Potential Tariffs: Trump's strategy includes prospective tariffs on pharmaceuticals, which could impact companies dependent on imports or international supply chains[1]. This could increase costs and potentially lead to higher drug prices for consumers, negatively affecting profitability for companies reliant on imported products.
2. Section 232 Investigation: The ongoing Section 232 investigation into the national security implications of pharmaceutical imports might pave the way for tariffs, further complicating international supply chains and potentially benefiting domestic producers[1].

Pricing and Market Dynamics

1. Most Favored Nations Policy: Trump's proposed "most favored nations" policy aims to reduce drug prices for Medicare by referencing international prices. This could lower revenues for pharmaceutical companies, potentially affecting their ability to invest in research and development[4].
2. Market Volatility: The biopharma sector has seen market volatility due to policy announcements, including a recent decline in the NASDAQ Biotechnology Index. This volatility could impact investor confidence and funding availability for biotech companies[4].

Industry Reaction and Adaptation

• Eli Lilly's Investment: Large companies are already responding to these policies, with Eli Lilly announcing substantial investments in U.S. manufacturing[3]. Other companies might follow suit to capitalize on streamlined approvals and tax incentives, potentially altering production strategies[3].
• Innovation and Development: The pharmaceutical industry argues that policies reducing drug prices could harm innovation by reducing investment in new drug development. This could especially affect smaller biotech firms, as they rely heavily on funding for R&D[4].

In summary, Trump's policies could lead to a more favorable regulatory environment for domestic pharmaceutical manufacturing but may also introduce challenges related to tariffs, inspections, and pricing policies. Companies will need to adapt their strategies to navigate these changes, potentially leading to shifts in global supply chains and investment patterns.

1. The recently announced customs duties by Trump on Monday are expected to affect not only the pharmaceutical products but also the active ingredients and medical devices used in their production, posing a risk for biotech companies.
2. Companies like Amgen, Eli Lilly, and AbbVie, with stable earnings and diversified product pipelines, are better equipped to handle the uncertainty caused by Trump's policies due to their strong financial standing and adaptability.
3. Trump's policies, including prospective tariffs on pharmaceuticals and the "most favored nations" policy aimed at reducing drug prices for Medicare, could lead to changes in the industry, such as shifts in global supply chains and increased investments in domestic manufacturing.

Read also: